The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 16, 2018
Filed:
May. 29, 2012
Michael Regnier, Bellevue, WA (US);
Michael Laflamme, Seattle, WA (US);
Charles Murry, Seattle, WA (US);
F. Steven Korte, Port Orchard, WA (US);
Scott Lundy, Shoreline, WA (US);
Stephen Denison Hauschka, Seattle, WA (US);
Jeffrey S. Chamberlain, Seattle, WA (US);
Guy Odom, Seattle, WA (US);
Michael Regnier, Bellevue, WA (US);
Michael Laflamme, Seattle, WA (US);
Charles Murry, Seattle, WA (US);
F. Steven Korte, Port Orchard, WA (US);
Scott Lundy, Shoreline, WA (US);
Stephen Denison Hauschka, Seattle, WA (US);
Jeffrey S. Chamberlain, Seattle, WA (US);
Guy Odom, Seattle, WA (US);
University of Washington, Seattle, WA (US);
Abstract
Compositions and methods for improving cardiac function, myocardial contractility and relaxation in a mammal are provided. Cardiomyocytes transfected with one or more expression vectors comprising a ribonucleotide reductase subunit R1-encoding nucleic acid sequence and a ribonucleotide reductase subunit R2-encoding nucleic acid sequence operably linked to a promoter are grafted to a mammalian myocardium. Also provided are compositions and methods for delivering dATP to a myocardium through grafting of donor cells overexpressing R1 and R2. dATP is thereby produced in situ and delivered through gap junctions established between donor cells and host cardiomyocytes. Alternatively, viral vector(s) having the R1 and R2-encoding construct(s) are administered to the mammal directly. Improvement of cardiac function can also be effected by administration of vectors comprising a nucleic acid sequence encoding a L48Q, 61 Q, or L57Q cTnC variant.